1inch 2cm 8ft have a nice day and good luck!
Answer:
Option d. an incense stick
Explanation:
because it produces smoke and it's smell attracts others.
Answer:
a. they can fix carbon at the lower CO2 concentrations that develop when the stomata are closed
Explanation:
C4 plants are those that have the capacity to fix CO2 even when a tiny concentration of it is available.
Desert condition is characterized by dryness and strong heat with both condition capable of creating water stress in plant as a result of evapotranspiration. In order to reduce evapotranspiration rate, desert plants (most C4 plants) close their stomata during the day.
<em>Stomata closure limit the diffusion of CO2 into desert plants and the small concentration of CO2 that results is utilized by a special enzyme in the plants.</em>
The correct option is a.
Sour milk contains less lactose than the fresh milk, as the sour milk gets converted to lactic acid and bacteria which enhances the digestion process. One important reason is that proteins take more time in getting digest than other nutrients. We know that fresh milk has a large amount of lactose.
Explanation:
The lactic acid bacteria have many benefits. They improve lactose digestion in the stomach. The lactase activity of the bacteria performs the task of digesting lactose in the product once it reaches the intestine thus fuelling the process of digestion in case of sour milk.
In fresh milk, the casein protein in contact with milk forms curdles which are difficult to digest.
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
